AstraZeneca PLC (NASDAQ:AZN – Free Report) – Investment analysts at Leerink Partnrs upped their FY2023 earnings estimates for AstraZeneca in a report released on Friday, November 17th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of $3.77 per share for the year, up from their prior forecast of $3.72. The consensus estimate for AstraZeneca’s current full-year earnings is $3.64 per share. Leerink Partnrs also issued estimates for AstraZeneca’s FY2024 earnings at $4.41 EPS.
A number of other research firms also recently issued reports on AZN. StockNews.com assumed coverage on shares of AstraZeneca in a report on Thursday, October 5th. They issued a “strong-buy” rating for the company. Erste Group Bank restated a “hold” rating on shares of AstraZeneca in a report on Friday, September 8th. Finally, Jefferies Financial Group upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Monday, September 25th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $103.00.
AstraZeneca Stock Performance
Shares of NASDAQ AZN opened at $64.13 on Monday. The company has a market cap of $198.79 billion, a PE ratio of 33.75, a price-to-earnings-growth ratio of 1.28 and a beta of 0.51. AstraZeneca has a 12 month low of $61.73 and a 12 month high of $76.56. The company has a debt-to-equity ratio of 0.60, a current ratio of 0.79 and a quick ratio of 0.60. The company has a 50-day simple moving average of $65.77 and a 200-day simple moving average of $68.96.
AstraZeneca (NASDAQ:AZN – Get Free Report) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.03. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $11.55 billion. AstraZeneca had a net margin of 13.10% and a return on equity of 30.30%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.84 earnings per share.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Americana Partners LLC lifted its position in AstraZeneca by 0.4% during the first quarter. Americana Partners LLC now owns 41,501 shares of the company’s stock valued at $2,881,000 after buying an additional 146 shares in the last quarter. Diversified Trust Co lifted its position in shares of AstraZeneca by 3.5% during the second quarter. Diversified Trust Co now owns 4,463 shares of the company’s stock worth $319,000 after purchasing an additional 151 shares in the last quarter. First Affirmative Financial Network lifted its position in shares of AstraZeneca by 2.9% during the third quarter. First Affirmative Financial Network now owns 5,495 shares of the company’s stock worth $372,000 after purchasing an additional 155 shares in the last quarter. Baldwin Brothers LLC MA lifted its position in shares of AstraZeneca by 4.2% during the second quarter. Baldwin Brothers LLC MA now owns 3,867 shares of the company’s stock worth $277,000 after purchasing an additional 156 shares in the last quarter. Finally, Wrapmanager Inc. lifted its position in shares of AstraZeneca by 4.1% during the second quarter. Wrapmanager Inc. now owns 3,962 shares of the company’s stock worth $284,000 after purchasing an additional 157 shares in the last quarter. 15.68% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Five stocks we like better than AstraZeneca
- What is a Secondary Public Offering? What Investors Need to Know
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Stock Market Sectors: What Are They and How Many Are There?
- MarketBeat Week in Review – 11/13 – 11/17
- Stock Splits, Do They Really Impact Investors?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.